ScripEquillium is hoping that unmet medical need and long-term efficacy will persuade the US Food and Drug Administration to approve itolizumab for acute graft-versus-host disease (aGVHD) despite its Phase
Pink SheetA single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and
Pink SheetThe Inflation Reduction Act (IRA)’s $2,000 Part D spending cap, which took effect on 1 January, is projected to help more than 11 million Medicare beneficiaries save $7bn on prescription drugs, accord
ScripPlanning for top-seller Jakafi’s (ruxolitinib) US patent expiration in 2028, Incyte reported positive top-line data from a pair of Phase III trials of selective JAK1 inhibitor povorcitinib in hidraden